Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C29H39NO2 |
| Molecular Weight | 433.6255 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C\C(=C/C1=CC=C(OCCN2CCOCC2)C=C1)C3=CC=C4C(=C3)C(C)(C)CCC4(C)C
InChI
InChIKey=OUQPTBCOEKUHBH-LSDHQDQOSA-N
InChI=1S/C29H39NO2/c1-22(24-8-11-26-27(21-24)29(4,5)13-12-28(26,2)3)20-23-6-9-25(10-7-23)32-19-16-30-14-17-31-18-15-30/h6-11,20-21H,12-19H2,1-5H3/b22-20+
| Molecular Formula | C29H39NO2 |
| Molecular Weight | 433.6255 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10378670
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10378670
Mofarotene is an analog of retinoic acid patented by a Swiss multinational healthcare company Hoffmann-La Roche as neoplasm inhibitors and agent for treating dermatoses. Like other retinoic acid agents, mofarotene binds to and activates retinoic acid receptors (RARs), thereby altering the expression of certain genes leading to cell differentiation and decreased cell proliferation in susceptible cells. Mofarotene has demonstrated considerable antitumor activity in a number of cancer cell lines. Mofarotene in combination with cisplatin and etoposide was studied in phase I clinical trials but further development was discontinued.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10378670
The doses of Ro 40-8757 ranged from 84 mg/m2 once daily to 42 mg/m2 thrice daily (tid).
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:59:55 GMT 2025
by
admin
on
Mon Mar 31 17:59:55 GMT 2025
|
| Record UNII |
8K3CVY8F8V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C804
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C63667
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
m7586
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
125533-88-2
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
100000080332
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
5467732
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
DTXSID7032006
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
8K3CVY8F8V
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
7114
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL146506
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY | |||
|
SUB09032MIG
Created by
admin on Mon Mar 31 17:59:55 GMT 2025 , Edited by admin on Mon Mar 31 17:59:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|